· Shares trading in a well defined range until approval.
· Uptrend is strong because of the ADCOM blowout vote.
· Short term resistance is strong because of the FDA delay.
· Possibility for short term decline to fill gap at 5.75.
· Excellent chance for profits exist for both traders and investors.